
    
      A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be
      randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks
      following treatment. Adaptive randomization will be used to balance treatment groups based on
      gender.
    
  